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dialysis care, the groin has again received attention as a
valuable hemodialysis access site in our institution. We,
therefore, reviewed our experience with angioaccess grafts
in the groin to assess safety and viability in our hemodial-
ysis patient population.
METHODS
Records from all groin hemodialysis access grafts
placed between June 1990 and February 1998 were
reviewed. All operations were performed at a single tertiary
care center by one of six surgeons. The grafts were polyte-
trafluoroethylene loop grafts placed from the common or
superficial femoral artery to the saphenous–common
femoral vein junction or directly to the common femoral
vein. Choice of specific polytetrafluoroethylene graft type
was made by the individual surgeon and included grafts
ranging from 6 mm to 8 mm in size made by manufactur-
ers that included Goretex (Flagstaff, Ariz), Impra
(Charlotte, NC), and Baxter (Irvine, Calif). Preoperative
screening for occlusive disease in the vascular laboratory
was performed at the surgeon’s discretion. All complica-
tions and subsequent treatment, including thrombosis,
infection, hematoma, psuedoaneurysm, steal, ischemia,
seroma formation, and stenosis, were recorded.
Graft patency and infection rates were analyzed with
life-table analysis and standards set by the Society for
Vascular Surgery/North American Chapter and the
International Society for Cardiovascular Surgery.8 As
stated by the ad hoc committee, “the graft is considered to
have ‘primary’ patency if it has had uninterrupted patency
with either no procedure performed on it or a procedure,
such as transluminal dilation or proximal or distal exten-
sion to the graft, to deal with disease progression in the
adjacent native vessel.”8 Secondary patency was defined as
the total life of the graft from insertion until discontinua-
tion or removal. Grafts that were functioning on last
During the past 30 years, dialysis access techniques
have undergone extensive changes. Historically, arteriove-
nous fistulae created for dialysis access have commonly
been placed in the upper extremity. In 1966, Brescia et al1
introduced an internal arteriovenous fistula between the
radial artery and the cephalic vein. Because some individ-
uals are not candidates for native fistulae, expanded poly-
tetrafluoroethylene grafts were developed and have been
shown to be suitable substitutes.2-5 As techniques for
hemodialysis access have evolved, different anatomic sites
have been used for arteriovenous access. Used bilaterally,
these include access sites with arterial inflow at the wrist,
brachial-based located in the forearm, brachial-based in
the upper arm, axillary-based in the upper arm or chest,
and femoral-based in the groin.
Angioaccess in the groin has received little attention
during the last two decades. Early experience with
hemodialysis access in the groin was discouraging because
of a high rate of infection and associated major limb
amputation.6,7 Currently, groin access grafts are used for
patients who have had failure of their upper extremity
sites caused by repeated thrombosis, arterial steal syn-
drome, severe axillary or subclavian arterial disease, and
venous obstruction. With the advent of polytetrafluo-
roethylene for prosthetic subcutaneous hemodialysis
access and with improvements in surgical techniques and
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Objective: Arteriovenous fistulae traditionally have been placed in the upper extremity. Experience with groin hemodial-
ysis access has been discouraging because of high infection rates and associated limb amputation. We reviewed our expe-
rience with angioaccess grafts in the groin to assess safety and viability in our hemodialysis patient population.
Methods: A retrospective review was performed of all groin hemodialysis access grafts placed at a single tertiary care cen-
ter between June 1990 and February 1998. Demographics, complications, and subsequent treatment were recorded.
Graft patency and infection rates were analyzed with life-table analysis.
Results: Data were collected on 73 graft insertions. A total of 52 episodes of thrombosis occurred in 26 grafts. Primary
patency rate was 71% at 1 year. Secondary patency rate was 83% at 1 year. There was a 22% incidence rate of infection.
Conclusion: We conclude that the incidence rate of infection and thrombosis in our series of femoral-based hemodialy-
sis grafts is comparable with rates reported in the literature for upper extremity polytetrafluoroethylene angioaccess
grafts. Although not considered a first choice, femoral artery–based hemodialysis access is a viable option when arterio-
venous fistulae in the upper extremity cannot be constructed. (J Vasc Surg 2002;35:691-3.)
follow-up examination but were discontinued for reasons
other than failure were censored in the life-table analysis.
RESULTS
Data were collected on 73 graft insertions in 73
patients. Demographic data are shown in the Table. A
total of 52 episodes of thrombosis occurred in 26 grafts.
Sixty-four percent of these were treated with thrombec-
tomy alone. Twenty-five percent of the thromboses were
treated with thrombectomy and curettage. Standard
embolectomy catheters were used for thrombectomy,
and metal curretts were used to currett intimal hyper-
plasia inside the graft. None of the thrombosed grafts
were treated with thrombolysis. As shown in Fig 1, the
primary patency rate was 71% at 1 year and 63% at 2
years. The secondary patency rate was 83% at 1 and 2
years (Fig 2).
Sixteen of 73 grafts (22%) had 17 episodes of infec-
tion, as identified with review of clinical charts. Four of
the 17 episodes of infection were cellulitis and were
treated with antibiotics alone. The other occurrences
involved frank infection of the graft and required surgery
for graft removal. All the infections occurred more than 1
month from the insertion date. Life-table analysis results
revealed a 15% infection rate at 6 months, 22% at 1 year,
and 24% at 2 and 3 years (Fig 3).
Complications of postcannulation hematomas,
pseudoaneurysms, and graft stenosis were 4%, 8%, and 7%,
respectively, during the follow-up period of the study. One
of three hematomas required evacuation with placement
of an interposition graft. Five of six grafts with pseudo-
aneurysms were treated with an interposition graft.
Stenoses occurred in five grafts and were corrected either
with radiographic angioplasty (n = 1), operative patch
angioplasty (n = 2), or interposition grafting (n = 2).
One episode of an ipsilateral major amputation
occurred. The patient had concomitant leg ischemia
worsened by steal from the graft with no revision possi-
ble because of limited arterial inflow. The patient chose
amputation of the extremity rather than discontinuation
of dialysis. General acceptance of lower extremity grafts
varied by patient. Some patients found their femoral
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Patient demographics
No. of patients
No. of patients 73
Mean age (years) 62
Sex (male:female ratio) 32:41
Race
White 41
Black 18
Hispanic 14
Cause of renal failure
Diabetes 21
Hypertension 33
Glomerulonephritis 11
Other 8
Fig 1. Life-table analysis results for primary patency rates. CI,
Confidence interval. Fig 2. Life-table analysis results for secondary patency rates. CI,
Confidence interval.
grafts uncomfortable and burdensome, but others pre-
ferred their femoral grafts to their previous upper
extremity grafts.
DISCUSSION
With the life-span of patients with end-stage renal dis-
ease undergoing hemodialysis continuing to rise,9 it is the
responsibility of the surgeon to create a strategy of dialysis
access that maximizes the use of potential access sites.
Ideally, any patient undergoing hemodialysis should
receive an autogenous fistula that could be accessed
throughout the patient’s life. Unfortunately, autogenous
access is often impossible because of the obliteration of
important superficial veins by prior medical intervention.
Therefore, many patients have a polytetrafluoroethylene
graft placed in an upper extremity. It is our impression
that, with modern surgical techniques, the groin deserves
renewed attention as a useful site for hemodialysis access.
Khadra, Dwyer, and Thompson10 reported the only
large series of groin grafts with which this series can be
compared. They reviewed 74 polytetrafluoroethylene loop
grafts placed in 61 patients. Twelve of 74 grafts (16%) had
complications involving graft infection, with a graft sal-
vage rate of more than 50% and no major limb amputa-
tion. The incidence rate of infection for our grafts was
22%, with no resultant amputation. This is comparable
with reports of upper extremity polytetrafluoroethylene
access infection rates that have been reported to range
from 12% to 25%.2-5 Furthermore, infections are usually a
result of graft cannulation and not a result of surgical cre-
ation.10 If careful consideration is given to sterile tech-
nique during cannulation, infection should not be a reason
to abandon the groin as a dialysis access site.
With regards to graft thrombosis, our primary patency
rate of 71% at 1 year compares favorably with a 1-year
patency rate of 50% shown by Khadra, Dwyer, and
Thompson.10 These primary patency rate results are simi-
lar to the 62% to 68% range reported for upper extremity
graft primary patency rate.2-4 Secondary patency rates are
also comparable. Multiple thrombectomies and graft revi-
sions may be necessary, but long-term graft survival can be
accomplished if the access is managed carefully and is not
significantly worse than upper extremity access.
In conclusion, we believe that femoral artery–based
hemodialysis access is a viable option on the basis of our
data. The incidence rate of infection and thrombosis is
comparable with upper extremity angioaccess, and the
amputation rate is acceptably low. Though not commonly
considered a first choice as a dialysis access site, the groin
should be considered a safe and practical option when
conventional arteriovenous fistulae in the upper extremity
can no longer be constructed.
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Fig 3. Life-table analysis results for infection rates. CI, Confidence
interval.
